Cargando…
Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes?
Whether the primary Hepatitis B vaccination confers lifelong protection is debated. The aim of the study was to assess the effectiveness of booster doses in mounting a protective HBV immune response in subjects vaccinated 18–20 years earlier. The study population consisted of vaccinated students att...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349749/ https://www.ncbi.nlm.nih.gov/pubmed/32429396 http://dx.doi.org/10.3390/vaccines8020227 |
_version_ | 1783557126614941696 |
---|---|
author | Papadopoli, Rosa De Sarro, Caterina Torti, Carlo Pileggi, Claudia Pavia, Maria |
author_facet | Papadopoli, Rosa De Sarro, Caterina Torti, Carlo Pileggi, Claudia Pavia, Maria |
author_sort | Papadopoli, Rosa |
collection | PubMed |
description | Whether the primary Hepatitis B vaccination confers lifelong protection is debated. The aim of the study was to assess the effectiveness of booster doses in mounting a protective HBV immune response in subjects vaccinated 18–20 years earlier. The study population consisted of vaccinated students attending medical and healthcare professions schools. A booster dose was offered to subjects with a <10 mIU/mL anti-HBs titer. The post-booster anti-HBs titer was evaluated after four weeks. The subjects with a <10 mIU/mL post-booster anti-HBs titer, received a second and third dose of the vaccine and after one month they were retested. A <10 mIU/mL anti-HBs titer was found in 35.1% of the participants and 92.2% of subjects that were boosted had a ≥10 mIU/mL post-booster anti-HBs titer, whereas 7.8% did not mount an anamnestic response. A low post-booster response (10–100 mIU/mL anti-HBs) was significantly more likely in subjects with a <2.00 mIU/mL pre-booster titer compared to those with a 2.00–9.99 mIU/mL pre-booster titer. The anamnestic response was significantly related to the baseline anti-HBs levels. A booster dose of the HBV vaccine may be insufficient to induce an immunological response in subjects with undetectable anti-HBs titers. A booster dose might be implemented when an anamnestic response is still present. |
format | Online Article Text |
id | pubmed-7349749 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73497492020-07-15 Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes? Papadopoli, Rosa De Sarro, Caterina Torti, Carlo Pileggi, Claudia Pavia, Maria Vaccines (Basel) Article Whether the primary Hepatitis B vaccination confers lifelong protection is debated. The aim of the study was to assess the effectiveness of booster doses in mounting a protective HBV immune response in subjects vaccinated 18–20 years earlier. The study population consisted of vaccinated students attending medical and healthcare professions schools. A booster dose was offered to subjects with a <10 mIU/mL anti-HBs titer. The post-booster anti-HBs titer was evaluated after four weeks. The subjects with a <10 mIU/mL post-booster anti-HBs titer, received a second and third dose of the vaccine and after one month they were retested. A <10 mIU/mL anti-HBs titer was found in 35.1% of the participants and 92.2% of subjects that were boosted had a ≥10 mIU/mL post-booster anti-HBs titer, whereas 7.8% did not mount an anamnestic response. A low post-booster response (10–100 mIU/mL anti-HBs) was significantly more likely in subjects with a <2.00 mIU/mL pre-booster titer compared to those with a 2.00–9.99 mIU/mL pre-booster titer. The anamnestic response was significantly related to the baseline anti-HBs levels. A booster dose of the HBV vaccine may be insufficient to induce an immunological response in subjects with undetectable anti-HBs titers. A booster dose might be implemented when an anamnestic response is still present. MDPI 2020-05-16 /pmc/articles/PMC7349749/ /pubmed/32429396 http://dx.doi.org/10.3390/vaccines8020227 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Papadopoli, Rosa De Sarro, Caterina Torti, Carlo Pileggi, Claudia Pavia, Maria Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes? |
title | Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes? |
title_full | Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes? |
title_fullStr | Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes? |
title_full_unstemmed | Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes? |
title_short | Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes? |
title_sort | is there any opportunity to provide an hbv vaccine booster dose before anti-hbs titer vanishes? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349749/ https://www.ncbi.nlm.nih.gov/pubmed/32429396 http://dx.doi.org/10.3390/vaccines8020227 |
work_keys_str_mv | AT papadopolirosa isthereanyopportunitytoprovideanhbvvaccineboosterdosebeforeantihbstitervanishes AT desarrocaterina isthereanyopportunitytoprovideanhbvvaccineboosterdosebeforeantihbstitervanishes AT torticarlo isthereanyopportunitytoprovideanhbvvaccineboosterdosebeforeantihbstitervanishes AT pileggiclaudia isthereanyopportunitytoprovideanhbvvaccineboosterdosebeforeantihbstitervanishes AT paviamaria isthereanyopportunitytoprovideanhbvvaccineboosterdosebeforeantihbstitervanishes |